Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
about
Targeting the apoptosis pathway in hematologic malignanciesSelection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesAnti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphomaLevels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7Murine models of B-cell lymphomas: promising tools for designing cancer therapiesCombinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsIntracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.Cell death in health and diseaseTRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.To kill a tumor cell: the potential of proapoptotic receptor agonistsAntitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey.Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.Understanding and circumventing resistance to anticancer monoclonal antibodies.Emerging antibody combinations in oncology.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Manipulating the apoptotic pathway: potential therapeutics for cancer patients.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.Cancer preventive effect of recombinant TRAIL by ablation of oncogenic inflammation in colitis-associated cancer rather than anticancer effect.
P2860
Q27024422-1135072A-4D1B-4611-9B96-69B362A7F981Q33421148-272460AE-5B9E-49D4-A042-CF240B4DA88BQ34139691-643F3F66-419B-4BFE-9F7B-99B7964C62F4Q34144940-1382616A-E48C-4468-A13D-46802F58742DQ34927264-880F9FF2-7C1D-449D-B5BB-B2974850480FQ35779492-3E0D59F4-5236-4291-BC9F-EB38DB4E3779Q35919697-D12A9B15-2C0A-4A66-A3D8-DBDD211DBC4FQ36366424-493740FC-4D1C-43D2-8291-60EB8C5B24F9Q36731174-AEA04D49-89E0-4B7B-8458-6D7116DDC42AQ37000481-67503AE0-F485-4FBA-BBAF-FE03462748D4Q37010413-F057973A-B528-4636-AC71-C66B86207411Q37016549-130E6621-37CE-4E99-BFCF-40EC1786BA02Q37181734-843BAEEA-D677-4543-8B75-A14761793F3AQ37412514-6FCBEFC9-B749-435F-A87C-8E3132243D78Q37448352-EEF61101-52DC-4214-A8E3-7466417AD82AQ37621564-8500EB9F-16C6-49EE-82B6-32586EC08BD6Q37672125-B481C709-E7B5-4577-B0B6-2E22090446ABQ37893414-CCAF2241-80FD-4753-8DE7-7DB80A00FE86Q37913356-8F2A3BE6-888F-4F4E-A23D-0044CCB66E9FQ38115574-894168D9-A57E-4E87-AC2D-BD3221C9F6ABQ38120535-B51DCB21-8B83-4EE7-AC5B-66591DF6E349Q38273851-A8AA7B7F-9DE8-439C-A5D4-622AAE10A6BCQ38868990-0290AC2E-9142-449F-B377-3E1880BA4E67Q38962519-561E2E32-6996-4846-B89B-880F3701DB85Q39013616-8E616E59-8628-4F92-BF39-5FE565E1F060Q39162763-FF5EAB00-BE73-4EA5-9804-5DBCC3F40C63Q39337154-68BAE420-AC7F-43FF-B476-B55DC8B175B9Q49567330-7509CFA3-21D1-4B91-94EF-F8F035EC1ECB
P2860
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@ast
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@en
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@nl
type
label
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@ast
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@en
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@nl
prefLabel
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@ast
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@en
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@nl
P2093
P1433
P1476
Cooperation of the proapoptoti ...... n-Hodgkin lymphoma xenografts.
@en
P2093
Alvin Gogineni
Avi Ashkenazi
Becky Yang
David A Lawrence
Dylan Daniel
Inessa Balter
Klara Totpal
Mary J Cole
Sarajane Ross
Sharon Fong Yee
P304
P356
10.1182/BLOOD-2007-02-076075
P407
P577
2007-08-27T00:00:00Z